Paraneoplastic Cerebellar Degeneration with Intracellular Antineuronal Antibodies: What to Do When Corticosteroid Therapy Has Not Been Sufficient
Clinical Scenario
Rapidly progressive cerebellar syndrome in which antineuronal antibodies directed against intracellular antigens have been detected. This antibody profile distinguishes the immunological context and is relevant to the selection of subsequent therapy.
Previous Line — Insufficient Response
Initial management prioritised treatment of the underlying tumor alongside first-line acute immunotherapy with corticosteroids (methylprednisolone). The goal was to reduce brain inflammation and levels of circulating antibodies. When those targets are not achieved, escalation to a further treatment step is indicated.
Next-Line Approach (partial — full protocol below)
The next step centres on antibody-clearing therapy — intravenous immunoglobulin (IVIG) or plasma exchange (PLEX) — aimed at reducing circulating autoantibodies. The specific indication criteria, timing relative to ongoing corticosteroid therapy, and the full decision framework are contained in the structured protocol.
References
DOI: 10.3390/brainsci11111414
- If a specific antibody has been detected, one can distinguish between antibodies directed against intracellular antigens and antibodies directed against cell-surface antigens.
- In the first case, regimens targeting T-cell based mechanisms might be of advantage.
- Reduction of circulating autoantibodies can also be addressed by intravenous immunoglobulins (IVIG) or plasma exchange (PLEX).
View source ↗